{"analyses":[{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.78","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.68","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"27","value":"4.1"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"38","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal","id":"OG000","title":"Chemotherapy"},{"description":"Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal","id":"OG001","title":"Chemotherapy + Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"Unstratified intention to treat population","reportingStatus":"POSTED","timeFrame":"within 6.5 years","title":"Progression Free Survival: Time to Event","type":"SECONDARY","unitOfMeasure":"Months"}